Kairos Pharma (KAPA) 17th Annual LD Micro Main Event Conference summary

Clinical trial progress and pipeline

• Phase two trial in prostate cancer supported by a $3.2M NIH grant; phase one trial in lung cancer fully funded by donors.

• Kairos-201 IND cleared for glioblastoma; strategic relationship with Cedars-Sinai enables rapid, cost-efficient trials.

• Pipeline includes drugs targeting immune suppression and reversing cancer drug resistance, with safety shown in over 600 patients.

• Biomarker identified to select responsive patients, increasing phase three trial success rates.

• Interim efficacy data expected in early 2025, with safety data readouts in the coming months.

Mechanism of action and innovation

• Central resistance mechanism identified: CD105 expression on cancer cells leads to drug resistance.

• Antibody developed to target CD105, restoring sensitivity to anti-androgen and anti-EGFR therapies.

• Mechanism relevant across multiple cancers: prostate, lung, breast, colon, head and neck.

• Kairos-101 and Kairos-201 enhance T-cell growth and target cancer stem cells; Kairos-401 and 102 modulate macrophages and T-cells for cancer and autoimmune diseases.

• Small molecule approach offers advantages over antibody therapies, reducing toxicity.

Market opportunity and competitive landscape

• Targeting large markets: $11.3B anti-androgen, $14B EGFR lung cancer, $118B immunotherapy.

• Tagrisso, a $5.8B drug, is a key focus for overcoming resistance.

• No known small pharma competitors directly targeting central resistance mechanisms.

• Approach complements, rather than competes with, large pharma drugs by extending their efficacy.